Clinical review report: Inotersen (Tegsedi) (Akcea therapeutics, inc.) indication: stage I or II polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of inotersen 189 mg/mL subcutaneous injection (administered as a 1.5 mL injection containing 300 mg inotersen sodium or 284 mg parent acid) for the treatment of stage I or stage II polyneuropathy in...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, January 2020
|
| Edition: | Version: final (with redactions) |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of inotersen 189 mg/mL subcutaneous injection (administered as a 1.5 mL injection containing 300 mg inotersen sodium or 284 mg parent acid) for the treatment of stage I or stage II polyneuropathy in adults with Hereditary transthyretin-mediated amyloidosis |
|---|---|
| Physical Description: | 1 PDF file (85 pages) illustration |